[go: up one dir, main page]

NO20080537L - Cycliske anilino-pyridinotriaziner - Google Patents

Cycliske anilino-pyridinotriaziner

Info

Publication number
NO20080537L
NO20080537L NO20080537A NO20080537A NO20080537L NO 20080537 L NO20080537 L NO 20080537L NO 20080537 A NO20080537 A NO 20080537A NO 20080537 A NO20080537 A NO 20080537A NO 20080537 L NO20080537 L NO 20080537L
Authority
NO
Norway
Prior art keywords
6alkyl
4alkyl
het1
pyrrolidinyl
hydrogen
Prior art date
Application number
NO20080537A
Other languages
English (en)
Other versions
NO341531B1 (no
Inventor
Kristof Van Emelen
Christopher John Love
Sven Franciscus Anna Van Brandt
Frederik Jan Rita Rombouts
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20080537L publication Critical patent/NO20080537L/no
Publication of NO341531B1 publication Critical patent/NO341531B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelsen vedrører forbindelsene med formel N-oksidformene, de farmasøytisk akseptable addisjonssaltene og de stereokjemisk isomere formene derav, hvor m representerer 1, n representerer 1, Z representerer N eller C, spesielt N; -X1- representerer C1-4alkyl, spesielt metyl; -X2- representerer -C1-4alkyl- eller -C1-4alkyl-NR7-, spesielt propyl, -etyl-NR7- eller -propyl-NR7-; -Y- representerer-NR2-C1-6alkyl-CO-NR4-, -Het1-C1-6alkyl-CO-NR5- eller -Het2-CO-NR6- og, hvor -C1-6alkyl-linkeren i -NR2-C1-6alkyl-CO-NR4- eller -Het1-C1-6alkyl-CO-NR5- valgfritt er substituert med én eller der hvor det er mulig to eller flere substituenter valgt fra hydroksy, halo og fenyl; R1 representerer hydrogen, klor, fluor eller brom; R2 representerer -C1-4alkyl-, spesielt etyl eller metyl; R7 representerer hydrogen; R8 representerer hydrogen; R4, R5 og R6 representerer hydrogen; Het1 er valgt fra piperazinyl eller piperidinyl, spesielt -piperazinyl; Het2 valgt fra pyrrolidinyl eller piperidinyl, spesielt pyrrolidinyl, hvor nevnte pyrrolidinyl valgfritt er substituert med hydroksy.
NO20080537A 2005-06-30 2008-01-29 Sykliske anilino-pyridinotriaziner NO341531B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105927 2005-06-30
PCT/EP2006/063555 WO2007003525A2 (en) 2005-06-30 2006-06-26 Cyclic anilino-pyridinotriazines as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
NO20080537L true NO20080537L (no) 2008-03-28
NO341531B1 NO341531B1 (no) 2017-12-04

Family

ID=37604825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080537A NO341531B1 (no) 2005-06-30 2008-01-29 Sykliske anilino-pyridinotriaziner

Country Status (19)

Country Link
US (1) US8778919B2 (no)
EP (1) EP1904461B1 (no)
JP (1) JP5345388B2 (no)
KR (1) KR101268354B1 (no)
CN (1) CN101341138B (no)
AT (1) ATE439349T1 (no)
AU (1) AU2006265205B2 (no)
BR (1) BRPI0612888B8 (no)
CA (1) CA2611438C (no)
DE (1) DE602006008474D1 (no)
EA (1) EA017545B1 (no)
ES (1) ES2330789T3 (no)
IL (1) IL188453A (no)
NO (1) NO341531B1 (no)
NZ (1) NZ564179A (no)
TW (1) TWI457340B (no)
UA (1) UA92608C2 (no)
WO (1) WO2007003525A2 (no)
ZA (1) ZA200711143B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
AU2003218735B2 (en) * 2002-03-13 2009-03-12 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
CA2549869C (en) * 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
CA2613889A1 (en) 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
WO2007082882A1 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
CA2631874C (en) 2006-01-19 2014-11-18 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8114876B2 (en) * 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5225104B2 (ja) * 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
MX2009000456A (es) * 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
EP2535336A1 (en) 2006-10-21 2012-12-19 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
RU2551772C2 (ru) 2008-02-21 2015-05-27 Сентокор Орто Байотек Инк. Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
ES2424982T3 (es) * 2008-03-10 2013-10-10 Janssen Pharmaceutica, N.V. 4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
AU2009267137A1 (en) * 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
MX2011004565A (es) 2008-10-31 2011-07-28 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
BRPI0921996A2 (pt) 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Métodos e composições para cultura e ligação de células em substratos planos.
EP3260534A1 (en) 2008-11-20 2017-12-27 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2456862A4 (en) 2009-07-20 2013-02-27 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
KR101785626B1 (ko) 2009-07-20 2017-10-16 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
KR101786735B1 (ko) 2009-07-20 2017-10-18 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
BR112012017761A2 (pt) 2009-12-23 2015-09-15 Centocor Ortho Biotech Inc diferenciação das células-tronco embrionárias humanas
PH12012501254A1 (en) 2009-12-23 2012-11-05 Janssen Biotech Inc Differentiation of human embryonic stem cells
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
JP6133776B2 (ja) 2010-08-31 2017-05-24 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の分化
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
AU2012355698B2 (en) 2011-12-22 2018-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
RU2018128383A (ru) 2012-03-07 2019-03-14 Янссен Байотек, Инк. Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
RU2018108850A (ru) 2012-06-08 2019-02-26 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки
MX2015008577A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Cultivo de celulas madre embrionarias humanas en la interfase aire-liquido para la diferenciacion en celulas endocrinas pancreaticas.
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
EP4039798A1 (en) 2012-12-31 2022-08-10 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells
SG10201707811XA (en) 2012-12-31 2017-11-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
WO2014180524A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
KR102162138B1 (ko) 2014-05-16 2020-10-06 얀센 바이오테크 인코포레이티드 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CA3066499A1 (en) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same
US11552262B2 (en) 2017-12-12 2023-01-10 Samsung Display Co., Ltd. Organic molecules for use in optoelectronic devices
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CN115010673B (zh) * 2022-07-21 2024-01-30 河南大学 可见光诱导无金属催化条件下合成1,3,5-三嗪类化合物的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442278A (en) * 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
ES2306671T3 (es) * 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2004009562A1 (en) * 2002-07-18 2004-01-29 Janssen Pharmaceutica, Nv Substituted triazine kinase inhibitors
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives

Also Published As

Publication number Publication date
JP2009500307A (ja) 2009-01-08
NO341531B1 (no) 2017-12-04
BRPI0612888B1 (pt) 2020-12-29
EA017545B1 (ru) 2013-01-30
CN101341138A (zh) 2009-01-07
WO2007003525A2 (en) 2007-01-11
IL188453A0 (en) 2008-08-07
TWI457340B (zh) 2014-10-21
AU2006265205B2 (en) 2011-06-30
ES2330789T3 (es) 2009-12-15
WO2007003525A3 (en) 2008-04-10
CN101341138B (zh) 2012-11-14
NZ564179A (en) 2010-09-30
TW200740818A (en) 2007-11-01
BRPI0612888A2 (pt) 2010-12-07
AU2006265205A1 (en) 2007-01-11
JP5345388B2 (ja) 2013-11-20
KR20080024223A (ko) 2008-03-17
CA2611438A1 (en) 2007-01-11
EA200800182A1 (ru) 2009-04-28
BRPI0612888A8 (pt) 2017-12-26
DE602006008474D1 (de) 2009-09-24
KR101268354B1 (ko) 2013-05-28
ZA200711143B (en) 2009-03-25
IL188453A (en) 2012-06-28
UA92608C2 (en) 2010-11-25
BRPI0612888B8 (pt) 2022-12-27
CA2611438C (en) 2014-01-07
US8778919B2 (en) 2014-07-15
US20100222574A1 (en) 2010-09-02
HK1128086A1 (en) 2009-10-16
EP1904461B1 (en) 2009-08-12
ATE439349T1 (de) 2009-08-15
EP1904461A2 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
NO341531B1 (no) Sykliske anilino-pyridinotriaziner
DK1732933T3 (da) Forobindelser til behandling af dyslipidæmi
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
CR8986A (es) Isoxazoles sustituidos como fungicidas
UA98116C2 (ru) Изоксазолины, композиция, их применение, способы получения и промежуточные соединения
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
TW200605879A (en) Pyrrolidinyl derivatives as 11-β hydroxysteroid dehydrogenase inhibitors
EA201170096A1 (ru) Замещенные производные пиримидона
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
TR201907373T4 (tr) Tetrazolinon bileşiği ve bunun kullanımı.
ATE478054T1 (de) Benzimidazolderivate
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
AR082773A1 (es) Agente de control de ectoparasitos animales
NO20071100L (no) 5-jodtetrazoler
TW200628446A (en) Substituted pyrrole derivative
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
AR057898A1 (es) Derivados de 3- acilindol, su preparacion y su aplicacion en terapeutica
TH91783B (th) ไซคลิค แอนิลิโน - พิริดิโนไทรแอซีน
NO20073426L (no) MTKI kinazolinderivater
TH91783A (th) ไซคลิค แอนิลิโน - พิริดิโนไทรแอซีน
TH1901003646A (th) สารประกอบ 7-เฟนิลเอธิลอะมิโน-4h-พิริมิโด[4,5-d] 1,3-ออกซะซิน-2-โอน ในฐานะเป็นตัวยับยั้ง idh1 และ idh2 ที่กลายพันธุ์